{
    "clinical_study": {
        "@rank": "52137", 
        "arm_group": [
            {
                "arm_group_label": "denovoDerm", 
                "arm_group_type": "Experimental", 
                "description": "Autologous tissue-engineered dermal substitute"
            }, 
            {
                "arm_group_label": "denovoSkin", 
                "arm_group_type": "Experimental", 
                "description": "Autologous tissue-engineered dermo-epidermal skin substitute"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is the evaluation of the safety of autologous tissue-engineered\n      dermal substitutes \"denovoDerm\" (first arm) and dermo-epidermal skin substitutes\n      \"denovoSkin\" (second arm) transplanted onto the wound bed in children and adolescents."
        }, 
        "brief_title": "Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects", 
        "completion_date": {
            "#text": "June 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Burn Injury", 
            "Soft Tissue Injury", 
            "Skin Necrosis", 
            "Scars", 
            "Congenital Giant Nevus", 
            "Skin Tumors"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Burns", 
                "Skin Neoplasms", 
                "Necrosis", 
                "Soft Tissue Injuries", 
                "Cicatrix", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Deep partial or full thickness skin defect of at least 9 cm2 requiring surgical wound\n             coverage due to:\n\n               1. Acute cases: burn injury, soft tissue injury, skin necrosis after purpura\n                  fulminans\n\n               2. Reconstructive cases (elective surgery): scar formation after burn injuries,\n                  congenital giant nevus, skin tumours\n\n          -  Informed consent by patients/parents or other legal representatives\n\n        Exclusion Criteria:\n\n          -  Infected wounds or positive general microbiological swabs taken from the nose for\n             multi-resistant germs\n\n          -  Patients tested positive for HBV, HCV, syphilis or HIV\n\n          -  Patients with known underlying or concomitant medical conditions that may interfere\n             with normal wound healing (e.g. immune deficiency, systemic skin diseases, any kind\n             of congenital defect of metabolism including diabetes)\n\n          -  Coagulation disorders as defined by INR outside its normal value, PTT >ULN and\n             fibrinogen <LLN and / or at the Investigator's discretion\n\n          -  Previous enrolment of the patient into the current study\n\n          -  Participation of the patient in another study within 30 days preceding and during the\n             present study\n\n          -  Patients or parents/other legal representatives expected not to comply with the study\n             protocol\n\n          -  Suspicion of child abuse\n\n          -  Pregnant or breast feeding females"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02145130", 
            "org_study_id": "EuroSkinGraft / ESG-01-2011"
        }, 
        "intervention": [
            {
                "arm_group_label": "denovoDerm", 
                "description": "Transplantation of an autologous tissue-engineered dermal substitute, covered with autologous split-thickness skin", 
                "intervention_name": "denovoDerm", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "denovoSkin", 
                "description": "Transplantation of autologous tissue-engineered dermo-epidermal skin substitute, no additional coverage needed", 
                "intervention_name": "denovoSkin", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Skin", 
            "Tissue-engineering", 
            "Autologous", 
            "Dermis", 
            "Epidermis"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "link": {
            "description": "EuroSkinGraft Consortium", 
            "url": "http://www.euroskingraft.eu"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland", 
                    "state": "ZH", 
                    "zip": "8032"
                }, 
                "name": "University Children's Hospital Zurich"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I Study to Evaluate the Safety of Autologous Tissue-engineered Dermal Substitutes and Autologous Dermo-epidermal Skin Substitutes for the Treatment of Large Deep Partial and Full Thickness Skin Defects in Children and Adolescents", 
        "overall_contact": {
            "last_name": "Ernst Reichmann, Prof", 
            "phone": "+41 634 89 11"
        }, 
        "overall_official": {
            "affiliation": "University Children's Hospital Zurich, Switzerland", 
            "last_name": "Martin Meuli, Prof", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Assessment/reporting of local infection rate", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "First time 4-6 days after transplantation"
            }, 
            {
                "description": "Assessment/reporting of graft take", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "First time 21 +/- 1 days after transplantation"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02145130"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Assessment/reporting of number of adverse events", 
            "measure": "Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "First time at day of transplantation"
        }, 
        "source": "University Children's Hospital, Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Children's Hospital, Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}